{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:45:41Z","timestamp":1792449941910,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clinical remission (CliR) achievement has been recognized as a new potential outcome in severe asthma. Nevertheless, we still lack a detailed profile of what features could better identify patients undergoing clinical remission. In this study, we aim to address this issue, tracing a possible identikit of patients fulfilling remission criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We enrolled 266 patients with severe eosinophilic asthma (SEA) treated with a 12-month course of anti-IL5\/IL5 receptor (IL5r) monoclonal antibodies. Patients with no exacerbation, OCS withdrawal, ACT \u2265 20 and FEV\n                      <jats:sub>1<\/jats:sub>\n                      \u2265 80% after 1 year of biologic treatment were classified as in clinical remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      30.5% of the enrolled patients achieved remission after biologic administration. CliR group showed a lower number of baseline asthma exacerbations and better lung function parameters, with a trend for higher ACT scores and a less frequent history of a positive skin prick test. CliR achievement was unlikely in presence of a higher BMI, a positive skin prick test, an increased number of asthma exacerbations before biologic treatment, anti-muscarinic administration, and a previous diagnosis of EGPA, bronchiectasis or osteoporosis. In contrast, a better lung function, an increased blood eosinophilic count, the presence of chronic rhinosinusitis with nasal polyps and a more frequent use of reliever therapy predicts remission development. Changes in exacerbations number, OCS use, ACT scores and FEV\n                      <jats:sub>1<\/jats:sub>\n                      % between remittent and non-remittent patients arise at specific follow up timepoints and are positively associated with CliR achievement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>anti-IL5\/IL5r biologics can induce CliR in a proportion of patients with SEA. Patients achieving remission demonstrate specific clinical, functional and inflammatory features, as well as a specific moment of improvement in all the CliR items.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1343362","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T23:20:01Z","timestamp":1705965601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Features of severe asthma response to anti-IL5\/IL5r therapies: identikit of clinical remission"],"prefix":"10.3389","volume":"15","author":[{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Portacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santi","family":"Nolasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Detoraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scioscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2022.04.005","article-title":"Can asthma biologics change the course of disease and induce drug-free remission","volume":"150","author":"Cohn","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"SANI definition of Clinical Remission in Severe Asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","author":"Thomas","year":"2023","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201cSuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1591443","article-title":"Treat to target approach for asthma","volume":"57","author":"Nannini","year":"2020","journal-title":"J Asthma"},{"key":"B12","article-title":"2022 GINA main report - global initiative for asthma - GINA","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1198\/016214506000000735","article-title":"The adaptive lasso and its oracle properties","volume":"101","author":"Zou","year":"2012","journal-title":"J Am Stat Assoc"},{"key":"B14","article-title":"Guideline on good pharmacovigilance practices (GVP) - Annex I - Definitions (Rev 4)","author":"Medicines Agency","year":"2017"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.PA1934","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.021","article-title":"Super-responders to biologic treatment in type 2-high severe asthma: passing fad or a meaningful phenotype","volume":"11","author":"Portacci","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/all.15473","article-title":"Biologics and airway remodeling in severe asthma","volume":"77","author":"Varricchi","year":"2022","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2018.10.6.614","article-title":"Lung function trajectory types in never-smoking adults with asthma: clinical features and inflammatory patterns","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13061020","article-title":"Clinical asthma remission obtained with biologics in real life: patients\u2019 Prevalence and characteristics","volume":"13","author":"Sposato","year":"2023","journal-title":"J Pers Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: A european multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/R\u03b1 biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00419-2023","article-title":"Real-world characteristics of \u201csuper-responders\u201d to Mepolizumab and Benralizumab in severe eosinophilic asthma and EGPA","volume":"9","author":"Portacci","year":"2023","journal-title":"ERJ Open Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1016\/j.jaip.2023.05.041","article-title":"Real-world effectiveness of IL-5\/5Ra targeted biologics in severe eosinophilic asthma with comorbid bronchiectasis","volume":"11","author":"Bendien","year":"2023","journal-title":"J Allergy Clin Immunol: In Practice"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123953","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with co-presence of bronchiectasis: A real-world multicentre observational study","volume":"12","author":"Campisi","year":"2023","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterization of eosinophilic bronchiectasis: A European multicohort study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01251-2020","article-title":"Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study","volume":"57","author":"Chalitsios","year":"2020","journal-title":"Eur Respir J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1016\/j.jaip.2023.05.021","article-title":"Clinical Communications The triple type 2 signature confers more frequent exacerbations and worse midexpiratory flow in moderate to severe asthma","volume":"11","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30049-9","article-title":"Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study","volume":"7","author":"Postma","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00408-022-00579-2","article-title":"Impact of biologic therapy on the small airways asthma phenotype","volume":"200","author":"Chan","year":"2022","journal-title":"Lung"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.01.029","article-title":"Real-life small airway outcomes in severe asthma patients receiving biologic therapies","volume":"9","author":"Chan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1343362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T23:20:05Z","timestamp":1705965605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1343362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2024.1343362"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1343362","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"article-number":"1343362"}}